

## Optiscan Mid-Year Results (July-December 2017)

### Highlights:

- Revenue up 186% (increased by \$593,613)
- Expenses reduced by 13% (reduced by \$337,869)
- Overall loss reduced by 54% (reduced by \$1,159,462)

Optiscan is pleased to follow up the recently released Appendix 4D and Financial Statements for the period ending 31 December 2017 with a summary of the release. Our revenue increased (increased by 186%: up \$593k), our expenses reduced (reduced by 13% : down \$338k) and a reduction in the loss for the period of \$1.16m (reduced by 54%). These results can be seen summarised below:

Summary	2017 (mid-year)	2016 (mid-year)	Var (2017 vs 2016)		Comment
Revenue	\$ 913,431	\$ 319,818	\$ 593,613	186%	Increased revenue
Expenses	\$ (2,269,376)	\$ (2,607,245)	\$ (337,869)	-13%	Reduced Expenses
Loss	\$ (1,005,235)	\$ (2,164,697)	\$ 1,159,462	-54%	Reduced Loss

### Performance Narrative (summary)

- The Company has achieved a number of key milestones over the half-year period, including the first demonstration of the collaboration product with Carl Zeiss Meditec (CZM) and the first sales of the ViewnVivo preclinical research product.
- During the Half-year to 31 December 2017, the Company continued with its new business model as noted below:
  - Continuing the development project with Carl Zeiss Meditec (CZM)
  - Sales of ViewnVivo – our second-generation pre-clinical research product; and
  - Exploring new market opportunities for related Optiscan products and services.
- Outlook
  - Optiscan expects to achieve several key milestones in terms of the commercialisation of its core endomicroscope technology during 2018, which should deliver an improved financial performance for Optiscan.
  - Importantly, over the next year, CZM is progressing regulatory approval for Convivo, with FDA and CE Mark approvals expected during 2018.
  - Optiscan will then move into the production phase as a company – this is a key milestone on the commercialisation pathway for the product and Optiscan as a whole.

Optiscan drives forward with a high level of confidence about the future of the business and its overall performance.

A special note of thanks to the team at Optiscan for their efforts through a tough but rewarding half year.

Yours sincerely,

Alan Hoffman  
Executive Chairman

### About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes and is now a global leader in the development and application of microscopic imaging technologies for Preclinical Research in science and life sciences as well as medical markets, such as neurosurgery. With the high cost of curative medicine, an opportunity exists for Optiscan's technology to be used globally to reduce costs and be used as a key tool for the early detection of disease, the effective treatment of disease and the improvement of treatment outcomes.